# Patient Tolerability Study of GSK163090

> **NCT00559299** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 20 (estimated)

## Conditions studied

- Depressive Disorder, Major
- Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** GSK163090

## Key facts

- **NCT ID:** NCT00559299
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2012-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00559299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00559299, "Patient Tolerability Study of GSK163090". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00559299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*